Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy

[1]  尚久 菊地.  第10回　Dystrophin：The Protein Product of the Duchenne Muscular Dystrophy Locus , 2018, The Japanese Journal of Rehabilitation Medicine.

[2]  John K. Hall,et al.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies. , 2016, Human molecular genetics.

[3]  D. MacArthur,et al.  Analysis of the ACTN3 heterozygous genotype suggests that α-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion. , 2016, Human molecular genetics.

[4]  E. McNally,et al.  Genotype-Specific Interaction of Latent TGFβ Binding Protein 4 with TGFβ , 2016, PloS one.

[5]  P. Shieh.  Duchenne muscular dystrophy: clinical trials and emerging tribulations. , 2015, Current opinion in neurology.

[6]  E. Hoffman,et al.  Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study , 2015, Annals of neurology.

[7]  Francesco Muntoni,et al.  Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  E. Hardeman,et al.  Properties of regenerated mouse extensor digitorum longus muscle following notexin injury , 2014, Experimental physiology.

[9]  T. Partridge,et al.  What Can We Learn From Clinical Trials of Exon Skipping for DMD? , 2014, Molecular therapy. Nucleic acids.

[10]  K. Quinlan,et al.  Evidence Based Selection of Commonly Used RT-qPCR Reference Genes for the Analysis of Mouse Skeletal Muscle , 2014, PloS one.

[11]  D. MacArthur,et al.  ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. , 2013, The Journal of clinical investigation.

[12]  D. Bishop,et al.  Genes for Elite Power and Sprint Performance: ACTN3 Leads the Way , 2013, Sports Medicine.

[13]  Craig McDonald,et al.  LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy , 2013, Annals of neurology.

[14]  Kerstin Pingel,et al.  50 Years of Image Analysis , 2012 .

[15]  E. Hoffman,et al.  Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model , 2012, Skeletal Muscle.

[16]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[17]  M. Rudnicki,et al.  Skeletal Muscle - one year on , 2012, Skeletal Muscle.

[18]  G. Lanfranchi,et al.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy , 2011, Neurology.

[19]  P. Miura,et al.  Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. , 2011, Human molecular genetics.

[20]  D. MacArthur,et al.  Deficiency of α-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling. , 2011, Human molecular genetics.

[21]  S. Head,et al.  The role of branched fibres in the pathogenesis of Duchenne muscular dystrophy , 2011, Experimental physiology.

[22]  K. North,et al.  Properties of extensor digitorum longus muscle and skinned fibers from adult and aged male and female Actn3 knockout mice , 2011, Muscle & nerve.

[23]  Nan Yang,et al.  Validation of an automated computational method for skeletal muscle fibre morphometry analysis , 2010, Neuromuscular Disorders.

[24]  S. Head.  Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue , 2010, Experimental physiology.

[25]  D. MacArthur,et al.  Alpha-actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. , 2010, Human molecular genetics.

[26]  B. Spiegelman,et al.  Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging , 2009, Proceedings of the National Academy of Sciences.

[27]  Y. Meckel,et al.  ACTN3 R577X Polymorphism and Israeli Top-level Athletes , 2009, International journal of sports medicine.

[28]  D. Burkin,et al.  Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy , 2009, Proceedings of the National Academy of Sciences.

[29]  F. Leturcq,et al.  Clinical Heterogeneity of Duchenne Muscular Dystrophy (DMD): Definition of Sub-Phenotypes and Predictive Criteria by Long-Term Follow-Up , 2009, PloS one.

[30]  L. Ferrucci,et al.  ACTN3 genotype is associated with muscle phenotypes in women across the adult age span. , 2008, Journal of applied physiology.

[31]  J. Chamberlain,et al.  Functional Deficits in nNOSμ-Deficient Skeletal Muscle: Myopathy in nNOS Knockout Mice , 2008, PloS one.

[32]  D. MacArthur,et al.  A gene for speed: contractile properties of isolated whole EDL muscle from an alpha-actinin-3 knockout mouse. , 2008, American journal of physiology. Cell physiology.

[33]  L. Ferrucci,et al.  ACTN3 Genotype is Associated with Muscle Phenotypes in Women across the Adult Age Span: 1353 , 2008 .

[34]  D. MacArthur,et al.  An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance. , 2008, Human molecular genetics.

[35]  D. MacArthur,et al.  Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans , 2007, Nature Genetics.

[36]  J. Morley,et al.  Branched fibers in dystrophic mdx muscle are associated with a loss of force following lengthening contractions. , 2007, American journal of physiology. Cell physiology.

[37]  D. MacArthur,et al.  Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks , 2007, European Journal of Human Genetics.

[38]  R. McCarter,et al.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy , 2007, Muscle & nerve.

[39]  E. Olson,et al.  Activated calcineurin ameliorates contraction‐induced injury to skeletal muscles of mdx dystrophic mice , 2006, The Journal of physiology.

[40]  D. Burkin,et al.  Severe muscular dystrophy in mice that lack dystrophin and α7 integrin , 2006, Journal of Cell Science.

[41]  S. Noguchi,et al.  Common pathological mechanisms in mouse models for muscular dystrophies , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  E. Hoffman,et al.  ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. , 2005, Journal of applied physiology.

[43]  S. Pandya,et al.  Practice Parameter: Corticosteroid treatment of Duchenne dystrophy , 2005, Neurology.

[44]  R. Griggs,et al.  Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[45]  S. Carbonetto,et al.  Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. , 2003, Human molecular genetics.

[46]  D. MacArthur,et al.  ACTN3 genotype is associated with human elite athletic performance. , 2003, American journal of human genetics.

[47]  A. McArdle,et al.  Damage to developing mouse skeletal muscle myotubes in culture: protective effect of heat shock proteins , 2003, The Journal of physiology.

[48]  R. Ahima,et al.  Functional improvement of dystrophic muscle by myostatin blockade , 2002, Nature.

[49]  D. V. Vander Woude,et al.  Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. , 2001, Human molecular genetics.

[50]  Eric P. Hoffman,et al.  Expression Profiling in the Muscular Dystrophies Identification of Novel Aspects of Molecular Pathophysiology , 2000 .

[51]  W. Winder,et al.  Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. , 2000, Journal of applied physiology.

[52]  E. Olson,et al.  Stimulation of Slow Skeletal Muscle Fiber Gene Expression by Calcineurin in Vivo * , 2000, The Journal of Biological Chemistry.

[53]  P. Even,et al.  Defective regulation of energy metabolism in mdx-mouse skeletal muscles. , 1994, The Biochemical journal.

[54]  G. Maréchal,et al.  Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch , 1993, Journal of Muscle Research & Cell Motility.

[55]  H. Sweeney,et al.  Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Stephenson,et al.  Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[57]  H. Blau,et al.  Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy , 1988, Cell.

[58]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[59]  K. Bushby,et al.  Validation of genetic modi fi ers for Duchenne muscular dystrophy : a multicentre study assessing SPP 1 and LTBP 4 variants , 2014 .

[60]  Michael P. Siegel,et al.  Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition. , 2013, Human molecular genetics.

[61]  C. Leeuwenburgh,et al.  Sarcopenia of aging: Underlying cellular mechanisms and protection by calorie restriction , 2009, BioFactors.

[62]  K. Uaesoontrachoon,et al.  Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. , 2008, The international journal of biochemistry & cell biology.

[63]  D. Latchman.  Protective effect of heat shock proteins in the nervous system. , 2004, Current Neurovascular Research.

[64]  S. Easteal,et al.  A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. , 1999, Nature genetics.